Skip to main content

Table 4 Cost effectiveness analysis over 6-month treatment duration: Base case analysis

From: The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Therapy Cost/patient (US$) QALYs gained/patient ICER (ΔC/ΔE) Comparator
Ibuprofen + PPI 1,314.50 0.34 3,866.18 No treatment
Celecoxib + PPI 1,422.80 0.40 1,805.00 Ibuprofen + PPI
Celecoxib* 1,543.50 0.37 Dominated -
Diclofenac + PPI* 1,565.30 0.35 Dominated -
Ibuprofen* 1,608.20 0.28 Dominated -
Diclofenac* 1,695.00 0.31 Dominated -
Etoricoxib + PPI 1,749.00 0.38 Dominated -
Etoricoxib 1,839.10 0.36 Dominated -
  1. *Simple dominance: Another option is less expensive and more effective
  2. ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
  3. ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option